|
1
|
Diaz JI, Mora LB and Hakam A: The mainz
classification of renal cell tumors. Cancer Control. 6:571–579.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rosner I, Bratslavsky G, Pinto PA and
Linehan WM: The clinical implications of the genetics of renal cell
carcinoma. Urol Oncol. 27:131–136. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Novara G, Ficarra V, Antonelli A, Artibani
W, Bertini R, Carini M, Cosciani Cunico S, Imbimbo C, Longo N,
Martignoni G, et al: Validation of the 2009 TNM version in a large
multi-institutional cohort of patients treated for renal cell
carcinoma: Are further improvements needed? Eur Urol. 58:588–595.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yoo NJ, Kim HS, Kim SY, Park WS, Kim SH,
Lee JY and Lee SH: Stomach cancer highly expresses both initiator
and effector caspases: An immunohistochemical study. APMIS.
110:825–832. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mitsiades N, Poulaki V, Mitsiades C and
Tsokos M: Ewing's sarcoma family tumors are sensitive to tumor
necrosis factor-related apoptosis-inducing ligand and express death
receptor 4 and death receptor 5. Cancer Res. 61:2704–2712.
2001.PubMed/NCBI
|
|
7
|
Liu LX, Liu ZH, Jiang HC, Qu X, Zhang WH,
Wu LF, Zhu AL, Wang XQ and Wu M: Profiling of differentially
expressed genes in human gastric carcinoma by cDNA expression
array. World J Gastroenterol. 8:580–585. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kolenko V, Uzzo RG, Bukowski R, Bander NH,
Novick AC, His ED and Finke JH: Dead or dying: Necrosis versus
apoptosis in caspase-deficient human renal cell carcinoma. Cancer
Res. 59:2838–2842. 1999.PubMed/NCBI
|
|
9
|
Kallakury BV, Karikehalli S, Haholu A,
Sheehan CE, Azumi N and Ross JS: Increased expression of matrix
metalloproteinases 2 and 9 and tissue inhibitors of
metalloproteinases 1 and 2 correlate with poor prognostic variables
in renal cell carcinoma. Clin Cancer Res. 7:3113–3119.
2001.PubMed/NCBI
|
|
10
|
Bhuvarahamurthy V, Kristiansen GO,
Johannsen M, Johannsen M, Loening SA, Schnorr D, Jung K and Staack
A: In situ gene expression and localization of metalloproteinases
MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in
human renal cell carcinoma. Oncol Rep. 15:1379–1384.
2006.PubMed/NCBI
|
|
11
|
Lin H, Pan JC, Zhang FM, Huang B, Chen X,
Zhuang JT, Wang H, Mo CQ, Wang DH and Qiu SP: Matrix
metalloproteinase-9 is required for vasculogenic mimicry by clear
cell renal carcinoma cells. Urol Oncol. 33:168.e9–16. 2015.
View Article : Google Scholar
|
|
12
|
Kawata N, Nagane Y, Igarashi T, Hirakata
H, Ichinose T, Hachiya T, Takimoto Y and Takahashi S: Strong
significant correlation between MMP-9 and systemic symptoms in
patients with localized renal cell carcinoma. Urology. 68:523–527.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kamiya N, Kishimoto T, Suzuki H, Sekita N,
Nagai Y, Oosumi N, Kito H, Tochigi N, Shinbo M, Nemori R, et al:
Increased in situ gelatinolytic activity in renal cell tumor
tissues correlates with tumor size, grade and vessel invasion. Int
J Cancer. 106:480–485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lein M, Jung K, Laube C, Hübner T,
Winkelmann B, Stephan C, Hauptmann S, Rudolph B, Schnorr D and
Loening SA: Matrix-metalloproteinases and their inhibitors in
plasma and tumor tissue of patients with renal cell carcinoma. Int
J Cancer. 85:801–804. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cho NH, Shim HS, Rha SY, Kang SH, Hong SH,
Choi YD, Hong SJ and Cho SH: Increased expression of matrix
metalloproteinase 9 correlates with poor prognostic variables in
renal cell carcinoma. Eur Urol. 44:560–566. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
DI Carlo A: Evaluation of neutrophil
gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9
(MMP-9) and their complex MMP-9/NGAL in sera and urine of patients
with kidney tumors. Oncol Lett. 5:1677–1681. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Di Carlo A: Matrix metalloproteinase-2 and
−9 in the sera and in the urine of human oncocytoma and renal cell
carcinoma. Oncol Rep. 28:1051–1056. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
DI Carlo A: Matrix metalloproteinase-2 and
−9 and tissue inhibitor of metalloproteinase-1 and −2 in sera and
urine of patients with renal carcinoma. Oncol Lett. 7:621–626.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schéele S, Nyström A, Durbeej M, Talts JF,
Ekblom M and Ekblom P: Laminin isoforms in development and disease.
J Mol Med (Berl). 85:825–836. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Durbeej M: Laminins. Cell Tissue Res.
339:259–268. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yurchenco PD and Patton BL: Developmental
and pathogenic mechanisms of basement membrane assembly. Curr Pharm
Des. 15:1277–1294. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miner JH and Yurchenco PD: Laminin
functions in tissue morphogenesis. Annu Res Cell Dev Biol.
20:255–284. 2004. View Article : Google Scholar
|
|
23
|
Patarroyo M, Tryggvason K and Virtanen I:
Laminin isoforms in tumor invasion, angiogenesis and metastasis.
Semin Cancer Biol. 12:197–207. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Morell-Quadreny L, Rubio J, Lopez-Guerrero
JA, Casanova J, Ramos D, Iborra I, Solsona E and Llombart-Bosch A:
Disruption of basement membrane, extracellular matrix
metalloproteinases and E-cadherin in renal-cell carcinoma.
Anticancer Res. 23:5005–5010. 2003.PubMed/NCBI
|
|
25
|
Lohi J, Tani T, Leivo I, Linnala A, Kangas
L, Burgeson RE, Lehto VP and Virtanen I: Expression of laminin in
renal-cell carcinomas, renal-cell carcinoma cell lines and
xenografts in nude mice. Int J Cancer. 68:364–371. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rissanen J, Korhonen M, Lehto VP and
Virtanen I: Laminin alpha1 chain in human renal cell carcinomas and
integrin-mediated adhesion of renal cell carcinoma cells to human
laminin isoforms. J Pathol. 200:157–167. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang H, Huo P, Hu G, Wei B, Kong D and Li
H: Identification of gene markers associated with metastasis in
clear cell renal cell carcinoma. Oncol Lett. 13:4755–4761. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sherief MH, Low SH, Miura M, Kudo N,
Novick AC and Weimbs T: Matrix metalloproteinase activity in urine
of patients with renal cell carcinoma leads to degradation of
extracellular matrix proteins: Possible use as a screening assay. J
Urol. 169:1530–1534. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sobin LH and Wittekind CH: International
Union Against Cancer (UICC) TNM classification of malignant tumors.
6th edition. Wiley-Liss; New York; pp. 193–195. 2002
|
|
30
|
Visse R and Nagase H: Matrix
metalloproteinases and tissue inhibitors of metalloproteinases
structure, function, and biochemistry. Circ Res. 92:827–839. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tian HY, Li ZX, Li HY, Wang HJ, Zhu XW and
Dou ZH: Effects of 14 single herbs on the induction of caspase-3 in
tumor cells: A brief review. Chin J Integr Med. 19:636–640. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Himelstein BP, Canete-Soler R, Bernhard
EJ, Dilks DW and Muschel RJ: Metalloproteinases in tumor
progression: The contribution of MMP-9. Invasion Metastasis.
14:246–258. 1994.-1995. PubMed/NCBI
|
